NVALT25/ELDAPT Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy.

Slides:

Advertisements

Similar presentations

Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine

Advertisements

CANOLFAN GOGLEDD CYMRU AR GYFER YMCHWIL GOFAL CYCHWYNNOL NORTH WALES CENTRE FOR PRIMARY CARE RESEARCH PRIFYSGOL BANGOR / BANGOR UNIVERSITY Developing and.

Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.

RTOG1106: Randomized Phase IIR Trial of Personalized Adaptive Radiotherapy Based on Mid-treatment FDG-PET in Locally Advanced NSCLC P.I.: Feng-Ming (Spring)

ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

Prospective Phase I/II Trial of Carbon Ion Radiotherapy for Locally Advanced Non-small-cell Lung Cancer (NSCLC) Abstract title: CIRT for Locally Advanced.

NDA SE-011 Docetaxel FDA Review. FDA Review Team Biostatistics –Clara Chu, PhD. –Gang Chen, PhD. Biopharmaceutics –Safaa Ibrahim PhD –Atiq Rahman,

Andrea Denicoff, RN, MS, ANP Clinical Investigations Branch, CTEP, DCTD CTEP Program Meeting March 18, 2009 CTEP Phase III Cancer Treatment Trials with.

MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.

24/09/041 SIR and the Management of Cancer Trial Data Kate Motohashi Gray Cancer Institute, Northwood, UK.

EUROPA UOMO The European Prostate Cancer Patients Coalition L. Denis Monaco, October 6,2006.

SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.

European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.

Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P)

ESMO 2011 Lung Cancer Vantage 014 Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Elderly Women Ovarian Cancer Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian.

Weekly Paclitaxel Combined with Monthly Carboplatin versus Single-Agent Therapy in Patients Age 70 to 89: IFCT-0501 Randomized Phase III Study in Advanced.

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.

ELIGIBILITY CRITERIA- Summarised

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.

Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC

S1400 Revisions #4/5 Training Slides

TMIST A Breast Cancer Screening Trial

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

A cura di Filippo de Marinis

N Engl J Med; Volume 373(17): ; October 22, 2015

Javelin A Phase III, open-label, multicenter trial of avelumab (MSB C) versus platinum-based doublet as a first-line treatment of recurrent or.

Overzicht activiteiten werkgroep medicamenteuze therapie

CLINICAL PROTOCOL DEVELOPMENT

ADSCaN A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer Rationale: Lung cancer.

Rosell R et al. Proc ASCO 2011;Abstract 7503.

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

OPTIMIZING TREATMENT FOR ADVANCED OVARIAN CANCER:

S1400 OVERVIEW / BACKGROUND

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Intervista a Lucio Crinò

Clinical Trials in STS Shreyaskumar Patel, M.D.

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Intervista a Cesare Gridelli

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Enhancing Patient Care in Advanced NSCLC Through Clinician-Patient Partnership.

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Locally Advanced NSCLC Implementing Innovation

More Than Meets the Eye.

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

Reporting in CRC screening

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.

Locally Advanced Lung Cancer

Domenica 03 giugno Highlight a cura di Filippo de Marinis

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

What’s new in stage III lung cancer?

Volume 6, Issue 6, Pages (June 2005)

LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.

George Blumenschein, MD, John V. Heymach, MD, PhD

MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Lung Cancer screening. The NELSON trial.

Using Q-learning Method in Identify Optimal Treatment Regime

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Treatment of Stage III Non-small Cell Lung Cancer

Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Presentation transcript:

NVALT25/ELDAPT Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy

Objective The primary objective of the project is to compare concurrent and sequential RCHT with respect to quality-adjusted survival (QAS) of elderly patients (≥75 years) with stage III NSCLC. Secondary objectives: To perform a geriatric assessment in stage III NSCLC patients to distinguish patients fit enough to undergo intensified treatment and to develop a reliable and clinically applicable geriatric screening instrument to guide treatment decisions in stage III NSCLC; To compare concurrent and sequential RCHT with respect to overall and progression free survival, overall and lung-cancer specific quality of life (QoL) and preservation of independence To compare cost-effectiveness of sequential and concurrent RCHT for elderly patients with stage III NSCLC To implement and disseminate the developed geriatric screening instrument in national and international guidelines

Study design: A multicentric randomized phase III trial comparing two treatment arms. Inclusion consists of 2 parts. All registered patients will undergo the first part, consisting of a geriatric assessment to assess vulnerability. Based on this assessment, fit patients are selected for part II: the randomized clinical trial. Study population: Patients with any subtype of NSCLC, primary UICC Stage III, age ≥ 75 years

Participating centres

Actives centers MUMC/MAASTRO clinic - open for inclusion since juni 2016 - 2 patients included Laurentius hospital - open for inclusion since november 2016

Opening soon (Q1 2017) VieCuri Canisius-Wilhelmina Ziekenhuis LUMC MC Haaglanden Radboudumc

issues Datamanagement Bloed-biomarkers

Study team & info PI’s: Prof. dr. A. Dingemans – MUMC Dr. J. van Loon – MAASTRO clinic Dr. M. Janssen-Heijnen – VieCuri Trial coordination: Michelle Neuhof - DCM- MAASTRO clinic eldapt@maastro.nl More info: www.eldapt.org password: kwfnvalt25